Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” the “Company”) today announced that Institutional Shareholder Services Inc.

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the most promising stocks according to Wall Street analysts. On June 26, ...

Researchers have found in a new systematic review and meta-analysis that higher levels of environmental pollutants and ...

The trial aims to assess the safety and efficacy of tralokinumab 300mg administered biweekly as a single agent.

The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, according to a retrospective study.

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Young patients with atopic dermatitis prioritize different treatment goals and have varying preferences from their caregivers.

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

Atopic dermatitis is a very common skin disease found in both adults and children. In fact, up to 10 to 20 percent of the population at some point suffers from atopic dermatitis.

Spongiotic dermatitis describes skin inflammation that causes swelling, redness, and itching. It's most often associated with ...

Atopic dermatitis and contact dermatitis may both have certain triggers that set off your flares. If you can avoid your triggers, you may be able to calm skin rashes or even prevent them.